2023-02-28 07:00 | UU:RNAZ | | News Release200 | TransCode Therapeutics Announces Orphan Drug Designation Status for TTX-MC138 for Treatment of Pancreatic Cancer |
2023-02-22 08:00 | UU:RNAZ | | News Release200 | TransCode Therapeutics and BRAIN Biotech join forces to develop a CRISPR-derived technology platform for cancer treatment |
2023-02-17 16:10 | UU:RNAZ | | News Release200 | TransCode Therapeutics Announces Closing of $1.5 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules |
2023-02-16 08:00 | UU:RNAZ | | News Release200 | TransCode Therapeutics Announces $1.5 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules |
2023-01-31 16:05 | UU:RNAZ | | News Release200 | TransCode Therapeutics Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-RIGA, in Melanoma |
2022-12-29 08:00 | UU:RNAZ | | News Release200 | TransCode Therapeutics Announces FDA Authorization to Proceed with First-In-Human Clinical Trial |
2022-12-06 16:20 | UU:RNAZ | | News Release200 | TransCode Therapeutics Announces Withdrawal of Registration Statement |
2022-11-30 07:00 | UU:RNAZ | | News Release200 | TransCode Therapeutics Announces eIND Submission to US FDA for Planned First-in-Human Clinical Trial in Patients with Advanced Solid Tumors |
2022-11-14 16:15 | UU:RNAZ | | News Release200 | TransCode Therapeutics Reports Third Quarter 2022 Results; Provides Business Update |
2022-11-09 07:00 | UU:RNAZ | | News Release200 | TransCode Therapeutics Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-siPDL1, in Pancreatic Adenocarcinoma |
2022-11-08 15:44 | UU:RNAZ | | News Release200 | Sidoti's November Micro-Cap Virtual Conference |
2022-11-07 08:00 | UU:RNAZ | | News Release200 | TransCode Therapeutics to Present at Sidoti Virtual Investor Conference |
2022-10-26 07:00 | UU:RNAZ | | News Release200 | TransCode Therapeutics Reports Positive Preclinical Results with its Lead Candidate, TTX-MC138, in Pancreatic Adenocarcinoma |
2022-10-19 08:02 | UU:RNAZ | | News Release200 | TransCode Therapeutics: Invitation to The ThinkEquity Conference |
2022-10-13 07:00 | UU:RNAZ | | News Release200 | TransCode Therapeutics Announces Publication of Feline Case Study in Frontiers in Oncology |
2022-09-27 08:00 | UU:RNAZ | | News Release200 | TransCode Therapeutics to Participate at the Chardan 6th Annual Genetic Medicines Conference |
2022-09-08 08:00 | UU:RNAZ | | News Release200 | TransCode Therapeutics Appoints MicroRNA Pioneer, Dr. Frank Slack, to its Advisory Board |
2022-08-15 16:15 | UU:RNAZ | | News Release200 | TransCode Therapeutics Reports Second Quarter 2022 Results; Provides Business Update |
2022-08-02 07:00 | UU:RNAZ | | News Release200 | TransCode Therapeutics and MD Anderson Announce Strategic Alliance to Advance RNA Therapies for Oncology |
2022-07-11 16:05 | UU:RNAZ | | News Release200 | TransCode Therapeutics Announces Expansion of Global RNA Oncology Patent Portfolio |
2022-06-09 09:00 | UU:RNAZ | | News Release200 | TransCode Therapeutics to Participate at BIO International Convention |
2022-06-01 09:00 | UU:RNAZ | | News Release200 | TransCode Therapeutics Receives National Institutes of Health (NIH) Notice of Award |
2022-05-20 09:00 | UU:RNAZ | | News Release200 | TransCode Therapeutics To Participate at H.C. Wainwright Global Investment Conference |
2022-05-19 09:00 | UU:RNAZ | | News Release200 | TransCode Therapeutics Acquires Option for Radiotheranostic Technology |
2022-05-16 08:30 | UU:RNAZ | | News Release200 | TransCode Therapeutics Reports First Quarter 2022 Results; Provides Business Update |
2022-04-13 09:00 | UU:RNAZ | | News Release200 | TransCode Therapeutics' CTO, Dr. Zdravka Medarova, to Moderate 7th Annual RNA Medicine Symposium |
2022-03-31 16:30 | UU:RNAZ | | News Release200 | TransCode Therapeutics Reports 2021 Results; Provides Business Update |